U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 36 results

Status:
US Approved Rx (2016)
First approved in 2003

Class (Stereo):
CHEMICAL (ABSOLUTE)



CRESTOR (rosuvastatin calcium) is an inhibitor of HMG-CoA reductase. It has been widely launched for the treatment of patients with dyslipidaemia and has also been approved in the US and EU to slow the progression of atherosclerosis.
Status:
US Approved Rx (2007)
First approved in 1996

Class (Stereo):
CHEMICAL (ABSOLUTE)



Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the e...
Status:
US Approved Rx (2008)
First approved in 1991

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of...
Status:
US Approved Rx (2004)
First approved in 1991

Class (Stereo):
CHEMICAL (ABSOLUTE)



BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and al...
Status:
US Approved Rx (2020)
First approved in 1987

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE). Lisinopril is marketed under the brand name ZESTRIL. ZESTRIL is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantl...
Status:
US Approved Rx (1984)
First approved in 1981

Class (Stereo):
CHEMICAL (RACEMIC)



Atenolol is a Beta-1 cardio-selective adreno-receptor blocking agent discovered and developed by ICI in 1976. Atenolol was launched in the market under the trade name Tenormin in 1976, and became the best-selling Beta-blocker in the world in the 1980...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Idoxifene (also known as CB 7432), a novel selective estrogen receptor modulator, is originally discovered at the CRC Centre for Cancer Therapeutics, Institute. This drug participated in clinical trials phase II in patients with locally advanced/meta...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)

Glenvastatin (HR780) is a synthetic HMG-CoA reductase (HMGCR) inhibitor. Like other statins, glenvastatin shows very low systemic bioavailability due to an extensive first pass effect at the intestinal and/or hepatic level. This is a positive trait, ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly tha...
Status:
US Previously Marketed
First approved in 1997

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cerivastatin (BAYCOL®) is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of sterols, including cholesterol. The inhibition of choles...